KuppingerCole's Advisory stands out due to our regular communication with vendors and key clients, providing us with in-depth insight into the issues and knowledge required to address real-world challenges.
Meet our team of analysts and advisors who are highly skilled and experienced professionals dedicated to helping you make informed decisions and achieve your goals.
Meet our business team committed to helping you achieve success. We understand that running a business can be challenging, but with the right team in your corner, anything is possible.
Back in November 2013 the U.S. congress enacted the Drug Supply Chain Security Act (DSCSA). Part of the regulation is that actors within the U.S. pharmaceutical industry must verify the U.S. state license, which is issued by the U.S. Drug Enforcement Administration (DEA), status (and thus the authenticity) of every trading partner within their supply chain. And this does not stop just by direct trading partners a pharmaceutical supply chain actor might have, the regulation states, that also indirect trading partner’s U.S. state license status must be proofed.
Back in November 2013 the U.S. congress enacted the Drug Supply Chain Security Act (DSCSA). Part of the regulation is that actors within the U.S. pharmaceutical industry must verify the U.S. state license, which is issued by the U.S. Drug Enforcement Administration (DEA), status (and thus the authenticity) of every trading partner within their supply chain. And this does not stop just by direct trading partners a pharmaceutical supply chain actor might have, the regulation states, that also indirect trading partner’s U.S. state license status must be proofed.
Co-founder and CEO
